Cardiac metastasis from renal cell carcinoma, especially without neoplastic thrombosis of the vena cava, is extremely rare. The prognosis of patients with metastatic renal cell carcinoma has been radically influenced by the introduction of tyrosine kinase inhibitors, but very few reports in the literature have described their activity in heart metastasis. We report the case of a woman with a left ventricle metastasis from kidney cancer without renal vein involvement, who was treated with pazopanib. The patient achieved a prolonged partial response, with clear signs of metastasis devascularization and a favorable toxicity profile.
ReynenK.: Frequency of primary tumors of the heart.Am J Cardiol, 77: 107, 1996.
2.
ButanyJ., LeongS.W., CarmichaelK., KomedaM.: A 30-year analysis of cardiac neoplasms at autopsy.Can J Cardiol, 21: 675–680, 2005.
3.
ReynenK., KöckeritzU., StrasserR.H.: Metastases to the heart.Ann Oncol, 15: 375–381, 2004.
4.
SzmitS., ZagrodzkaM., KurzynaM., OpolskiG., SzczylikC.: Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma.Cardiology, 114: 67–71, 2009.
ZustovichF., GottardoF., De ZorziL., CecchettoA., Dal BiancoM., MauroE., CarteiG.: Cardiac metastasis from renal cell carcinoma without inferior vena involvement: a review of the literature based on a case report.Two different patterns of spread? Int J Clin Oncol, 13: 271–274, 2008.
7.
ZhangB., MaloufJ., YoungP., KohliM., DroncaR.: Cardiac metastasis in renal cell carcinoma without vena cava or atrial involvement: an unusual presentation of metastatic disease.Rare Tumors, 5. e29, 2013.
8.
ChengH., ForceT.: Why do kinase inhibitors cause cardiotoxicity and what can be done about it?Prog Cardiovasc Dis, 53(2): 114–120, 2010.
9.
SternbergC.N., DavisI.D., MardiakJ., SzczylikC., LeeE., WagstaffJ., BarriosC.H., SalmanP., GladkovO.A., KavinaA., ZarbáJ.J., ChenM., McCannL., PanditeL., RoychowdhuryD.F., HawkinsR.E.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.J Clin Oncol, 28(6): 1061–1068, 2010.
10.
MotzerR.J., HutsonT.E., CellaD., ReevesJ., HawkinsR., GuoJ., NathanP., StaehlerM., de SouzaP., MerchanJ.R., BoletiE., FifeK., JinJ., JonesR., UemuraH., De GiorgiU., HarmenbergU., WangJ., SternbergC.N., DeenK., McCannL., HackshawM.D., CrescenzoR., PanditeL.N., ChoueiriT.K.: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.N Engl J Med, 369(8): 722–731, 2013.
